問卷

TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

更新時間:2023-09-19

張平穎
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

159Cases

2020-07-01 - 2026-01-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2016-11-01 - 2025-12-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated11Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-01-01 - 2016-12-31

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2023-06-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-12-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2016-04-01 - 2018-12-31

Phase I

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
  • Condition/Disease

    Breast Cancer

  • Test Drug

    Oraxol

Participate Sites
6Sites

Terminated6Sites

趙大中
Taipei Veterans General Hospital

Division of Radiation Therapy

2017-09-01 - 2021-12-31

Phase I

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
  • Condition/Disease

    Breast Cancer

  • Test Drug

    Oraxol

Participate Sites
7Sites

Terminated6Sites

2017-04-27 - 2018-12-31

Phase I

A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
  • Condition/Disease

    Gastric Cancer/Esophageal Cancer/Gastro-esophageal Cancer

  • Test Drug

    Oraxol + Ramucirumab

Participate Sites
7Sites

Terminated6Sites

2018-09-01 - 2019-02-28

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2018-10-16 - 2019-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites